Antiseizure Medications in Pregnancy Linked to Poor Fetal Growth Risk
Personalized briefing
Discovery of the day · Neurology
Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
This prospective cohort study from the EURAP international registry demonstrates that prenatal exposure to antiseizure medications is independently associated with an elevated risk of poor fetal growth, in addition to previously established risks of congenital malformations and neurodevelopmental effects. The researchers found that risk varied significantly across individual monotherapies and specific drug combinations, with the risk increasing as the number of concomitant antiseizure medications rose. These findings provide critical data for preconception counselling and individualized treatment selection in women with epilepsy, underscoring the need to weigh fetal growth outcomes alongside neurological disease control when optimizing therapeutic regimens.
Novelty
78%
Rigor
94%
Significance
91%
Validity
93%
Clarity
88%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
